UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).
Designed and developed using BenevolentAI’s scientific and technical expertise, BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery.
BenevolentAI has dosed the first patient in its clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).
With nine vaccines now showing they can powerfully prevent severe illness and death from #COVID19—and vaccines in short supply—researchers are mulling an issue that, even a few months ago, was only hypothetical: Should people mix and match vaccines that require two shots?
Scarce vaccine supplies ramp up interest in combining different doses.
An Israeli drug that has been successful in initial trials, could hold a key in blunting the COVID-19 pandemic. Thirty patients in serious condition participated in the trial and all recovered, most of them in less than a week. Sonya Cohen was one of them and she could one day be seen as a walking #miracle.
Follow Jerusalem Dateline and download the CBN News app to ensure you keep receiving news from a Christian Perspective. go.cbn.com/cbnapp.
#covidcure #Israel #Israeli #innovation #fightcovid #breakthrough.
Ichilov Hospital, Tel Aviv
Many researchers are already working on developing vaccines for the next pandemic, even though they don’t know what it will be. (Craig Chivers/CBC.
When the next coronavirus pandemic hits, scientists plan to already have a vaccine against it, no matter what it is. But how is that possible? Here’s what they’re doing now to develop vaccines against emerging viruses and future variants of COVID-19.
Popular energy drinks may give you a boost, but they may also contribute to possible serious heart conditions, findings show.
A team of researchers, led by a Texas A&M University professor, has found that some energy drinks have adverse effects on the muscle cells of the heart.
The study, led by Dr. Ivan Rusyn, a professor in the Veterinary Integrative Biosciences (VIBS) Department at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVMBS), was published in Food and Chemical Toxicology. In it, researchers observed cardiomyocytes – human heart cells grown in a laboratory – exposed to some energy drinks showed an increased beat rate and other factors affecting cardiac function.
57:03 “A tool that would be used for millenia.”
Foresight biotech & health extension group sponsored by 100 plus capital.
Accelerator applications are open now: https://foresight.org/biotech-health-extension-program.
Industry blindspots: Unincentivized work that could dramatically advance progress on aging.
SONIA ARRISON, 100 Plus Capital.
The adeno-associated viruses often used as vectors to deliver gene therapy can trigger unwanted and sometimes dangerous immune responses. Now, a Harvard University team led by renowned geneticist George Church, Ph.D., has developed a way to “cloak” AAVs from immune surveillance. They’ve spun off Ally Therapeutics to develop it.
